• Case-Based Modules
• Hepatitis A
• Hepatitis B
• Hepatitis C
• Common Management Issues
• Health Educator
• Home

Monitoring and Management of Patients on Therapy for Chronic Hepatitis B

You answered:

As soon as the patient obtains an undetectable HBV DNA level, it is advisable for him to stop therapy.

This answer is incorrect. If a patient stops therapy at the first instance of an undetectable HBV DNA, it is quite likely that the HBV DNA will rebound, possibly causing a flare of hepatitis. For HBeAg-positive patients, antiviral therapy should be continued for at least 6 months after the HBV DNA is undetectable and HBeAg seroconversion has occurred.

Choose another answer:

	For HBeAg-positive patients, monitoring for HBeAg seroconversion should occur only after the patient has achieved HBsAg seroconversion.
	After starting therapy, the patient should have his ALT and HBV DNA level next measured at the end of 1 year of therapy.
	If the patient’s HBV DNA level declines by 1 log10 after 6 months of therapy, the response is termed a primary non-response.

[Back to Question | Go to Correct Answer]